NO991162L - Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR) - Google Patents

Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR)

Info

Publication number
NO991162L
NO991162L NO991162A NO991162A NO991162L NO 991162 L NO991162 L NO 991162L NO 991162 A NO991162 A NO 991162A NO 991162 A NO991162 A NO 991162A NO 991162 L NO991162 L NO 991162L
Authority
NO
Norway
Prior art keywords
kdr
monoclonal antibodies
extracellular domain
receptor protein
vegf receptor
Prior art date
Application number
NO991162A
Other languages
English (en)
Norwegian (no)
Other versions
NO991162D0 (no
Inventor
Andreas Menrad
Karl-Heinz Thierauch
Georg Martiny-Baron
Frank Totzke
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO991162D0 publication Critical patent/NO991162D0/no
Publication of NO991162L publication Critical patent/NO991162L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO991162A 1996-09-11 1999-03-10 Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR) NO991162L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19638745A DE19638745C2 (de) 1996-09-11 1996-09-11 Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
PCT/EP1997/004928 WO1998011223A1 (fr) 1996-09-11 1997-09-09 Anticorps monoclonaux diriges contre le domaine extracellulaire de la proteine du recepteur kdr de vegf humain

Publications (2)

Publication Number Publication Date
NO991162D0 NO991162D0 (no) 1999-03-10
NO991162L true NO991162L (no) 1999-05-06

Family

ID=7806450

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991162A NO991162L (no) 1996-09-11 1999-03-10 Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR)

Country Status (12)

Country Link
US (1) US6344339B1 (fr)
EP (1) EP0925359A1 (fr)
JP (1) JP2001501920A (fr)
AU (1) AU730287B2 (fr)
CA (1) CA2265927A1 (fr)
DE (1) DE19638745C2 (fr)
HU (1) HUP9904052A3 (fr)
IL (1) IL128406A0 (fr)
NO (1) NO991162L (fr)
PL (1) PL332034A1 (fr)
WO (1) WO1998011223A1 (fr)
ZA (1) ZA978204B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2299099A (en) * 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
NO983911D0 (no) * 1998-08-26 1998-08-26 Norsk Hydro As Alginatkapsler til bruk ved behandling av hjernesvulst
JP2002529421A (ja) * 1998-11-06 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 血管過浸透性の阻害方法
CA2361553A1 (fr) * 1999-01-29 2000-08-03 Zhenping Zhu Anticorps specifiques au kdr et leurs utilisations
EP1130032A1 (fr) * 2000-02-28 2001-09-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Anticorps monochaines reconnaissant le récepteur humain de type 2 du facteur de croissance vasculaire endothéliale (VEGFR-2/KDR)
PL414997A1 (pl) 2001-02-19 2016-02-29 Novartis Ag Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do leczenia guzów litych nerki
DE60219617T2 (de) 2001-05-16 2008-01-03 Novartis Ag Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
KR20120125398A (ko) 2002-05-16 2012-11-14 노파르티스 아게 암에서 ｅｄｇ 수용체 결합제의 용도
EP2014678B1 (fr) 2002-09-12 2011-11-02 Oncotherapy Science, Inc. Peptides KDR et vaccins les comportant
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
CA2524048C (fr) 2003-05-19 2013-06-25 Irm Llc Composes immunosuppresseurs et compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GB0400122D0 (en) * 2004-01-06 2004-02-11 Badrilla Ltd Method of quantifying binding
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2377555A3 (fr) 2004-11-18 2011-11-23 Imclone LLC Anticorps contre le récepteur 1 du facteur de croissance endothéliale vasculaire
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2009510073A (ja) 2005-09-27 2009-03-12 ノバルティス アクチエンゲゼルシャフト カルボキシアミン化合物およびその使用方法
ES2481671T3 (es) 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
CN1987468B (zh) * 2005-12-23 2012-01-11 上海交通大学医学院附属仁济医院 血管内皮生长因子时间分辨荧光免疫分析方法及试剂盒
RU2447891C2 (ru) 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
CA2649792A1 (fr) 2006-05-09 2007-11-15 Novartis Ag Combinaison comprenant un chelatant du fer et un agent antineoplasique et ses applications
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
CA2668235A1 (fr) 2006-11-02 2008-06-05 Yale University Estimation de la competence d'ovocytes
EP2125895B1 (fr) * 2007-02-02 2015-04-08 Vegenics Pty Ltd Antagoniste du recepteur de facteurs de croissance pour l'allo-immunite de greffe d'organe et l'arteriosclerose
AU2008216327A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
WO2009118305A1 (fr) 2008-03-26 2009-10-01 Novartis Ag Inhibiteurs de désacétylases b à base d'hydroxamate
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
EP2344161B1 (fr) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinaisons d'une camptothécine de liposome soluble dans l'eau avec du cetuximab ou du bevacizumab
JP5805538B2 (ja) * 2008-11-07 2015-11-04 リサーチ ディベロップメント ファウンデーション Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法
MX2011006610A (es) 2008-12-18 2011-06-30 Novartis Ag Nueva forma polimorfica de acido 1-(4-{l-[(e)-4-ciclohexil-3 -trifluorometil-benciloxi-imino]-etil)-2-etil-bencil)-azetidin-3 carboxilico.
WO2010080455A1 (fr) 2008-12-18 2010-07-15 Novartis Ag Nouveaux sels
KR20170062554A (ko) 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
MY155570A (en) 2009-06-26 2015-10-30 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
US20120149661A1 (en) 2009-08-26 2012-06-14 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
BR112012005400A2 (pt) 2009-09-10 2016-04-05 Irm Llc derivados do tipo éter de heteroarilas bicíclicas
CN102596951B (zh) 2009-11-04 2015-04-15 诺华股份有限公司 用作mek抑制剂的杂环磺酰胺衍生物
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
GEP20135998B (en) 2009-12-08 2013-12-25 Novartis Ag Heterocyclic sulfonamide derivatives
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
WO2012035078A1 (fr) 2010-09-16 2012-03-22 Novartis Ag Inhibiteurs de la 17α-hydroxylase/c17,20-lyase
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
EP2702052B1 (fr) 2011-04-28 2017-10-18 Novartis AG Inhibiteurs de 17a-hydroxylase/c17,20-lyase
CA2838029A1 (fr) 2011-06-09 2012-12-13 Novartis Ag Derives de sulfonamide heterocyclique
WO2012175487A1 (fr) 2011-06-20 2012-12-27 Novartis Ag Composés de cyclohexyl-isoquinolinone
WO2012175520A1 (fr) 2011-06-20 2012-12-27 Novartis Ag Dérivés d'isoquinolinone substitués par un hydroxy
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
EP2794592A1 (fr) 2011-12-23 2014-10-29 Novartis AG Composés inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2794591A1 (fr) 2011-12-23 2014-10-29 Novartis AG Composés inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison
JP2015503517A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
WO2013149581A1 (fr) 2012-04-03 2013-10-10 Novartis Ag Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (fr) 2013-01-22 2014-07-31 Novartis Ag Composés de purinone substitués
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
WO2014155268A2 (fr) 2013-03-25 2014-10-02 Novartis Ag Inhibiteurs de kinase tyrosine fgf-r et leur utilisation dans le traitement de maladies associées à un manque ou à une absence d'activité snf5
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
WO2015022663A1 (fr) 2013-08-14 2015-02-19 Novartis Ag Composés et compositions utiles comme inhibiteurs de mek
WO2015022664A1 (fr) 2013-08-14 2015-02-19 Novartis Ag Composés et compositions utiles comme inhibiteurs de mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2015191602A2 (fr) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Polythérapies ciblant un stroma associé à une tumeur ou des cellules tumorales
RU2695230C2 (ru) 2014-07-31 2019-07-22 Новартис Аг Сочетанная терапия
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
AU2017217677A1 (en) 2016-02-08 2018-07-26 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
US10543231B2 (en) 2017-05-19 2020-01-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP2020525470A (ja) * 2017-07-03 2020-08-27 ディヴェロップメント センター フォー バイオテクノロジー 抗ｖｅｇｆｒ抗体及びその使用
EP3697425A1 (fr) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Procédés et composés pour une thérapie par cellules immunitaires améliorées
CA3083660A1 (fr) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anticorps anti-trem2 et methodes associees
EP3730483B1 (fr) 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Classe d'inhibiteurs de kinase dérivés de pyrimidine
WO2021097256A1 (fr) 2019-11-14 2021-05-20 Cohbar, Inc. Peptides antagonistes de cxcr4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors

Also Published As

Publication number Publication date
WO1998011223A1 (fr) 1998-03-19
HUP9904052A2 (hu) 2000-03-28
NO991162D0 (no) 1999-03-10
IL128406A0 (en) 2000-01-31
HUP9904052A3 (en) 2002-01-28
ZA978204B (en) 1998-03-03
DE19638745A1 (de) 1998-03-12
DE19638745C2 (de) 2001-05-10
US6344339B1 (en) 2002-02-05
PL332034A1 (en) 1999-08-16
CA2265927A1 (fr) 1998-03-19
AU4622297A (en) 1998-04-02
JP2001501920A (ja) 2001-02-13
EP0925359A1 (fr) 1999-06-30
AU730287B2 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
NO991162D0 (no) Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR)
CY2008003I2 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
DE69617896T2 (de) Humaner monoklonaler Antikörper gegen VEGF
DE69535459D1 (de) Monoklonale antikörper spezifisch gegen vegf-rezeptoren und ihre verwendung
EE200100336A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
NO975621L (no) Höyaffinitets-humane monoklonale antistoff spesifikke for RSV F-protein
NO980915D0 (no) Rekombinante anti-CD4-antistoff egnet for human terapi
DE69628652D1 (de) Vegf-verwandtes protein
NO972016D0 (no) Indolyl-Y-reseptorantagonister
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
DE69728392D1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
ATE244571T1 (de) Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
ATE258548T1 (de) Adhäsionsrezeptor-antagonisten
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
WO1999046379A3 (fr) Proteines receptrices humaines; reactifs et procedes associes
AU2299099A (en) Antibodies against human vegf receptor kdr
EP0749445A4 (fr) Anticorps de fixant au domaine extracellulaire du recepteur du facteur de croissance des colonies de granulocytes g-csf et procedes de traitement
FI946006A0 (fi) Humaani-rinoviruksen reseptoriproteiinin multimeerisiä muotoja
ITMI922854A1 (it) Uso degli antagonisti dei recettori 5-ht3
DE69617010D1 (de) Isazole derivate als fibrinogen-rezeptor-antagonisten
BR9603432A (pt) Antagonistas de receptores de endotelina
WO1999019480A3 (fr) Proteines receptrices humaines et reactifs et methodes associes
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
DE69714031D1 (de) Nachweis von änderungen des humanen h2-rezeptoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application